Rohto Pharmaceutical Co.,Ltd.
Simbolis: 4527.T
JPX
3200
JPYRinkos kaina šiandien
23.2296
P/E santykis
0.8870
PEG koeficientas
730.04B
MRK kapitalizacija
- 0.01%
DIV pajamingumas
Rohto Pharmaceutical Co.,Ltd. (4527-T) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 79951 | 72791 | 52964 | ||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 1008 | 661 | -1199 | ||||||||||||||||
balance-sheet.row.net-receivables | 0 | 60656 | 51682 | 47865 | ||||||||||||||||
balance-sheet.row.inventory | 0 | 41062 | 33527 | 27925 | ||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 29547 | 24678 | 20975 | ||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 190246 | 164306 | 133071 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 66182 | 62839 | 49790 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 2564 | 2954 | 4014 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 6997 | 6338 | 3521 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 9561 | 9292 | 7535 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 32629 | 27471 | 27425 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 5371 | 5297 | 4606 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 5686 | 5419 | 3361 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 119429 | 110318 | 92717 | ||||||||||||||||
balance-sheet.row.other-assets | 0 | 2 | 3 | 2 | ||||||||||||||||
balance-sheet.row.total-assets | 0 | 309677 | 274627 | 225790 | ||||||||||||||||
balance-sheet.row.account-payables | 0 | 16025 | 13660 | 9603 | ||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 4177 | 8033 | 2312 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 6230 | 3185 | 6138 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 7516 | 13350 | 5787 | ||||||||||||||||
Deferred Revenue Non Current | 0 | 3146 | 3387 | 5126 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 29368 | 27256 | 10008 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 14439 | 19311 | 12708 | ||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 1184 | 1184 | 179 | ||||||||||||||||
balance-sheet.row.total-liab | 0 | 94601 | 90799 | 69179 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0 | 6504 | 6504 | 6504 | ||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 184005 | 162195 | 145511 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 18705 | 8735 | 3167 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 354 | 851 | 725 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 209568 | 178285 | 155907 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 309677 | 274627 | 225790 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 5508 | 5543 | 704 | ||||||||||||||||
balance-sheet.row.total-equity | 0 | 215076 | 183828 | 156611 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||
Total Investments | 0 | 33637 | 28132 | 26226 | ||||||||||||||||
balance-sheet.row.total-debt | 0 | 11693 | 21383 | 8099 | ||||||||||||||||
balance-sheet.row.net-debt | 0 | -68258 | -51408 | -44865 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 34290 | 27953 | 23006 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 7801 | 7673 | 6748 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -11277 | 458 | 3402 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | -7560 | -30 | 2464 | ||||||||||||||||
cash-flows.row.inventory | 0 | -6105 | -3061 | 3188 | ||||||||||||||||
cash-flows.row.account-payables | 0 | 1716 | 3323 | -2811 | ||||||||||||||||
cash-flows.row.other-working-capital | 0 | 672 | 226 | 561 | ||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 110 | -8834 | -13148 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -9908 | -11328 | -10304 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -1582 | -1203 | -1516 | ||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -5940 | -5615 | -2206 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 2641 | 1963 | 4050 | ||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 1613 | -223 | -261 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -13176 | -16406 | -10237 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | -8761 | -3133 | -1880 | ||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | -4676 | -3422 | -2965 | ||||||||||||||||
cash-flows.row.other-financing-activites | 0 | -2762 | 10025 | 2498 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -16199 | 3470 | -2347 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 5236 | 4335 | 96 | ||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 6786 | 18651 | 7589 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 77691 | 70905 | 52254 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 70905 | 52254 | 44665 | ||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 30924 | 27250 | 20008 | ||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -9908 | -11328 | -10304 | ||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 21016 | 15922 | 9704 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 238664 | 199646 | 181053 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 101243 | 83157 | 74326 | ||||||||||||||||
income-statement-row.row.gross-profit | 0 | 137421 | 116489 | 106727 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | 0 | -63 | 246 | 260 | ||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 103457 | 87135 | 83732 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 204700 | 170292 | 158058 | ||||||||||||||||
income-statement-row.row.interest-income | 0 | 962 | 368 | 341 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 247 | 248 | 145 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 751 | -240 | 1139 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -63 | 246 | 260 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 751 | -240 | 1139 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 247 | 248 | 145 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 7801 | 7673 | 6748 | ||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | 0 | 33959 | 29349 | 22990 | ||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 34290 | 27953 | 23006 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 7860 | 6803 | 6236 | ||||||||||||||||
income-statement-row.row.net-income | 0 | 26377 | 21127 | 16743 |
Dažnai užduodami klausimai
Kas yra Rohto Pharmaceutical Co.,Ltd. (4527.T) bendras turtas?
Rohto Pharmaceutical Co.,Ltd. (4527.T) bendras turtas yra 309677000000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.582.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 74.691.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.117.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.154.
Kas yra Rohto Pharmaceutical Co.,Ltd. (4527.T) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 26377000000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 11693000000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 103457000000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 0.000.